National Institutes of Health: Leukemia trials

The registry lists 318 Leukemia studies with National Institutes of Health as lead sponsor. 7 are open to participants now and 104 have results posted.

Early Phase 1 1Phase 1 166Phase 2 147Phase 3 10No phase 29(a study in two phases counts in both)

Studies

Page 3 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic LeukemiaTerminatedNCT00098488Phase 1
• Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
• Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaTerminatedNCT00096148Phase 2
• Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasTerminatedNCT00096005Phase 1
• XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
• S0432 Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00093418Phase 2
• Cilengitide in Treating Patients With Acute Myeloid LeukemiaTerminatedNCT00089388Phase 2
• Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00089349Phase 2
• 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomasCompletedNCT00089271Phase 1
• Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00089154Phase 2
• Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00087425Phase 2
• Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
• CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00086840Phase 2
• LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaCompletedNCT00085150Phase 1
• CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
• Music Imagery for Patients Receiving Chemotherapy for Leukemia or Non-Hodgkin's LymphomaCompletedNCT00082303Phase 1/2
• T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaCompletedNCT00079404Phase 1
• Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
• Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous LeukemiaCompletedNCT00079313Phase 2
• Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
• 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic MalignanciesCompletedNCT00077181Phase 1
• Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic LeukemiaCompletedNCT00076180Phase 1
• Sleep, Fatigue, and Dexamethosone in Children With LeukemiaCompletedNCT00075101Phase 3
• GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00070551Phase 1
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
• Peripheral Stem Cell Transplant in Treating Patients With High-Risk LeukemiaTerminatedNCT00066417Phase 2
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00062075Phase 2
• Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or LymphomaTerminatedNCT00060112Phase 1
• Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT00058461Phase 2
• Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaCompletedNCT00058227Phase 1
• Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00054431Phase 2
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaCompletedNCT00053963Phase 1
• Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
• Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic LeukemiaCompletedNCT00049569Not applicable
• Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00049192Phase 2
• A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)CompletedNCT00045396Phase 2
• Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT00042796Phase 1
• Brain Neoplasms, Leukemia and Petrochemical ExposuresCompletedNCT00042445
• Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic CancerActive, not recruitingNCT00039676
• Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00039117Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
• Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic LeukemiaWithdrawnNCT00030355Phase 1/2
• Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to TherapyCompletedNCT00030108Phase 1
• Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic LeukemiaCompletedNCT00025038Phase 2
• BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaWithdrawnNCT00024115Phase 1
• Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
• Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic LeukemiaTerminatedNCT00022971Phase 1
• Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic LeukemiaCompletedNCT00022737Phase 3
• Tipifarnib in Treating Young Patients With Refractory LeukemiaCompletedNCT00022451Phase 1
• Immunotoxin Therapy in Treating Patients With Hairy Cell LeukemiaCompletedNCT00021983Phase 1
• Caspofungin Acetate in Treating Children With Fever and NeutropeniaCompletedNCT00020527Not applicable
• Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or LymphomaCompletedNCT00020111Phase 1
• UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or LeukemiaCompletedNCT00019838Phase 1
• Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic CancerCompletedNCT00019656Phase 1
• Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic LeukemiaWithdrawnNCT00019409Phase 3
• Monoclonal Antibody Therapy in Treating Patients With LeukemiaCompletedNCT00019227Phase 1/2
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00019032Phase 1
• Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's LymphomaCompletedNCT00018954Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00017472Phase 1
• Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00016302Not applicable
• Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute LeukemiaCompletedNCT00016016Phase 1/2
• STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00015834Phase 1/2
• Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)CompletedNCT00015587
• Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic MalignanciesCompletedNCT00013533Early Phase 1
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Thalidomide With or Without Fludarabine in Treating Patients With Hematologic CancerTerminatedNCT00009984Phase 2
• Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00006364Phase 2
• Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
• Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00006240Phase 2
• Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00006226Phase 2
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
• Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
• Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedNCT00005942Phase 1/2
• Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous TreatmentCompletedNCT00005811Phase 2
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiaTerminatedNCT00005786Not applicable
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
• Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00004862Phase 1
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00003997Phase 1
• Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or LymphomaCompletedNCT00003970Phase 1
• Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00003934Phase 3
• 506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT00003837Not applicable
• Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT00003694Phase 2
• Flavopiridol in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00003620Phase 2
• 506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00003545Phase 2
• Raltitrexed in Treating Children With Refractory Acute LeukemiaCompletedNCT00003528Phase 1
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00003190Phase 3